Share This Article:

What Prevents Eligible Patients from Receiving Progesterone Therapy to Prevent Recurrent Preterm Birth

Abstract Full-Text HTML Download Download as PDF (Size:279KB) PP. 395-398
DOI: 10.4236/ojog.2014.47059    3,303 Downloads   3,936 Views  

ABSTRACT

Objective: The use of intramuscular 17-alpha-hydroxyprogesterone caproate (17-OHPC) has been shown to be beneficial for the prevention of preterm birth (PTB) in women with a prior history. Not all patients with a prior preterm birth receive 17-OHPC. The purpose of this study was to investigate potential barriers to receiving this therapy. Methods: A retrospective chart review of those patients at our institution who received the diagnosis of “previous preterm delivery” in 2010 and 2011 was performed to see whether they were offered and received 17-OHPC. Patients were considered eligible if they had a prior delivery at less than 36 weeks of gestation secondary to idiopathic preterm labor. For those patients that were deemed eligible but did not receive therapy, an explanation was sought. Results: Sixty-six charts were reviewed in detail. Forty-three patients were considered eligible to receive 17-OHPC. The remaining had medical indications for delivery including premature rupture of membranes (PROM) (15), intrauterine growth restriction (IUGR) (1), and hypertension (2). Of the 43 patients deemed eligible, 17 did not receive 17-OHPC. Of these, eight patients were not offered therapy, 2 patients declined therapy, 3 patients presented with therapy after 28 weeks (too late), and 4 received a prophylactic cerclage as their only therapy. There were no significant differences between the two groups. Conclusion: In an effort to increase 17-OHPC use among eligible patients, we must continually identify physician biases and patient barriers that prevent utilization of this intervention. In addition, patients who deliver preterm should be told the importance of presenting early in subsequent pregnancies in order to receive the full benefits of this therapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Meyer, A. , Cipparrone, N. , Buras, A. and Parilla, B. (2014) What Prevents Eligible Patients from Receiving Progesterone Therapy to Prevent Recurrent Preterm Birth. Open Journal of Obstetrics and Gynecology, 4, 395-398. doi: 10.4236/ojog.2014.47059.

References

[1] Meis, P.J., Klebanoff, M., Thom, E., et al. (2003) Prevention of Recurrent Preterm Delivery by 17-Alpha-Hydroxy-progesterone Caproate. The New England Journal of Medicine, 348, 2379-2385. http://dx.doi.org/10.1056/NEJMoa035140
[2] ACOG Committee Opinion (2008) Use of progesterone to Reduce Preterm Birth. Obstetrics & Gynecology, 112, 963-965, Number 419, October 2008.
[3] How, H.Y., Barton, J.R. and Istwan, N.B. (2007) Prophylaxis with 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Delivery: Does Gestational Age at Initiation of Treatment Matter? American Journal of Obstetrics & Gynecology, 197, e1-e4.
[4] Society for Maternal-Fetal Medicine Publications Committee, with Assistance of Vincenzo Berghella (2012) Progesterone and Preterm Birth Prevention: Translating Clinical Trials Data into Clinical Practice. American Journal of Obstetrics & Gynecology, 206, 376-386.
[5] Spong, C.Y., Meis, P.J., Thom, E.A., et al. (2005) Progesterone for Prevention of Recurrent Preterm Birth: Impact of Gestational Age at Previous Delivery. American Journal of Obstetrics & Gynecology, 193, 1127-1131. http://dx.doi.org/10.1016/j.ajog.2005.05.077
[6] da Fonseca, E.B., Bittar, R.E., Carvalho, M.H. and Zugaib, M. (2003) Prophylactic Administration of Progesterone by Vaginal Suppository to Reduce the Incidence of Spontaneous Preterm Birth in Women at Increased Risk: A Randomized Placebo-Controlled Double-Blind Study. American Journal of Obstetrics & Gynecology, 188, 419-424. http://dx.doi.org/10.1067/mob.2003.41
[7] Romero, R., Nicolaides, K., Conde-Agudelo, A., et al. (2012) Vaginal Progesterone in Women with an Asymptomatic Sonographic Short Cervix in the Midtrimester Decreases Preterm Delivery and Neonatal Morbidity: A Systematic Review and Metaanalysis of Individual Patient Data. American Journal of Obstetrics & Gynecology, 206, 124, e1-e19.
[8] O’Brien, J.M. (2013) Mortality Related to 17-OHPC Exposure Is an Important Safety Outcome. Letter to the Editor. American Journal of Obstetrics & Gynecology, 209, 282-283.
http://dx.doi.org/10.1016/j.ajog.2013.04.028
[9] Senat, M.V., Porcher, R., Winer, N., et al. (2013) Prevention of Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate in Asymptomatic Twin Pregnancies with a Short Cervix: A Randomized Controlled Trial. American Journal of Obstetrics & Gynecology, 208, e1-e8.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.